24/7
Buzz
Startups
VC
AI
Innovation
Opinions
Events
Promising Startups 2024
BiblioTech
Boarding Pass
Corporate
Appointments
CTalk
Tech Gateways
2025 VC survey
@Finance
Ctech Testimonials
Shopping
Projects
Spotlight
About
Newsletter
Contact us
Facebook
Twitter
ACCESSIBILITY
by
Homepage
Anchiano
Tags search
HOME
24/7
buzz
STARTUPS
VC
AI
Innovation
OPINIONS
EVENTS
SHOPPING
ABOUT
teram of use
Privacy Policy
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
19:02
Germany signs second $3.1 billion Arrow missile deal with Israel
17:51
Full list of Israeli startup M&As in 2025
17:47
Dell acquires AI data-infrastructure startup Dataloop in $120 million all-cash deal
14:36
The AI revolution is already here - and this time, it’s not waiting for anyone
More stories
Buzz
Most popular
Daily
Weekly
1
Palo Alto Networks CEO: “We’re happy Wiz is now part of Google, it gives us more room to operate”
2
Cyera raises $400 million at $9 billion valuation in Blackstone-led round
3
Vega raises $120 million Series B as two-year-old cyber startup hits $700 million valuation
4
“Younger people are getting cancer more and more. We have to make kinder medicines.”
5
UAE reportedly behind Elbit’s record $2.3 billion defense deal
More news
Anchiano
2 stories about Anchiano
Anchiano Therapeutics Schedules TASE Delisting
14.03.19
|
Lilach Baumer
Based in Jerusalem and Cambridge, Massachusetts, clinical-stage Anchiano develops gene therapies for cancer, with a special focus on bladder cancer
Cancer Treatment Company Anchiano Therapeutics Wants to List on Nasdaq
09.01.19
|
Lilach Baumer
The company formerly known as BioCanCell submitted a prospectus to the SEC on Monday, with Oppenheimer & Co. as the sole underwriter
